These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 4282509)

  • 1. [The effect of plasmin from cadaveric plasma on fibrinogen and fibrin].
    Levin GIa
    Prikl Biokhim Mikrobiol; 1974; 10(5):688-90. PubMed ID: 4282509
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nature of lytic effect of fibrinogen-heparin and thyroxine-heparin complexes on fibrin].
    Kudriashov BA; Liapina LA; Molchanova LV; Rustamova BA
    Vopr Med Khim; 1970; 16(2):161-8. PubMed ID: 4247358
    [No Abstract]   [Full Text] [Related]  

  • 4. [Action of anti-plasmin in activation of the fibrinolysis system and its clinical management].
    Tabara C; Hitano E; Mizuno Y; Kazama M; Abe H
    Rinsho Byori; 1974 Oct; 22(10 Suppl):105. PubMed ID: 4281036
    [No Abstract]   [Full Text] [Related]  

  • 5. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of plasmin by fibrinogen.
    Higazi AA; Mayer M
    Biochem J; 1990 Jul; 269(2):299-302. PubMed ID: 2143650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels.
    Smith JD; Chen A; Ernst LA; Waggoner AS; Campbell PG
    Bioconjug Chem; 2007; 18(3):695-701. PubMed ID: 17432824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative determination of fibrin and fibrinogen in biological material.
    Haeberli A; Straub PW
    J Lab Clin Med; 1980 Aug; 96(2):258-66. PubMed ID: 6447180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
    Sakata Y; Aoki N
    J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrochemical processing of fibrinogen modified-graphite surfaces: effect on plasmin generation from adsorbed plasminogen.
    Alfonsi-Hourdin S; Longchamp S; Gallet O; Nigretto JM
    Biomaterials; 2006 Jan; 27(1):52-60. PubMed ID: 16029886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of lytic effect on fibrin of immobilized heparin in complex with plasma proteins].
    Platé NA; Valuev LI; Gumirova FKh; Maklakova IA
    Vopr Med Khim; 1982; 28(5):19-23. PubMed ID: 6217639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
    Sangrar W; Koschinsky ML
    Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis inhibitors.
    Davis GL
    Clin Lab Sci; 1997; 10(4):212-8. PubMed ID: 10169620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic activity of the vitreous body.
    Forrester JV; Prentice CR; Williamson J; Forbes CD
    Invest Ophthalmol; 1974 Nov; 13(11):875-9. PubMed ID: 4279343
    [No Abstract]   [Full Text] [Related]  

  • 17. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer indicate cancer-related fibrin deposition and fibrinolysis.
    Gerner C; Steinkellner W; Holzmann K; Gsur A; Grimm R; Ensinger C; Obrist P; Sauermann G
    Thromb Haemost; 2001 Mar; 85(3):494-501. PubMed ID: 11307821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibrinogen fragment D - inhibitor of fibrinolytic processes].
    Rozenfel'd MA; Fateeva LA; Gontar' ID
    Biokhimiia; 1983 Jul; 48(7):1135-40. PubMed ID: 6225469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.